Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum-Reference-Cited by-同舟云学术

Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum

Published:2019-06-05 Issue: Volume:10 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Singh Susheel K.,Thrane Susan,Chourasia Bishwanath K.,Teelen Karina,Graumans Wouter,Stoter Rianne,van Gemert Geert-Jan,van de Vegte-Bolmer Marga G.,Nielsen Morten A.,Salanti Ali,Sander Adam F.,Sauerwein Robert W.,Jore Matthijs M.,Theisen Michael

Funder

Udenrigsministeriet

Strategiske Forskningsråd

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference43 articles.

1. Transmission blocking malaria vaccines;Carter;Vaccine.,2001

2. Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito;Vermeulen;J Exp Med.,1985

3. Plasmodium falciparum transmission blocking monoclonal antibodies recognize monovalently expressed epitopes;Vermeulen;Dev Biol Stand.,1985

4. Toward the development of effective transmission-blocking vaccines for malaria;Nikolaeva;Expert Rev Vaccines.,2015

5. Cloning and expression of the gene coding for the transmission blocking target antigen Pf s48/45 of Plasmodium falciparum;Kocken;Mol Biochem Parasitol.,1993

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Malaria vaccines: a new era of prevention and control;Nature Reviews Microbiology;2024-07-18

2. IgM plays a prominent role in naturally acquired immunity againstPlasmodium falciparumgametocytes;2024-07-02

3. A Self-Assembling Pfs230D1-Ferritin Nanoparticle Vaccine Has Potent and Durable Malaria Transmission-Reducing Activity;Vaccines;2024-05-16

4. A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trial;BMC Medicine;2024-04-23

5. A randomized first-in-human phase I trial of differentially adjuvanted Pfs48/45 malaria vaccines in Burkinabé adults;Journal of Clinical Investigation;2024-04-01